Predicting antipsychotics response in an animal model investigating neuroimmune-dopamine interactions and its translation into a schizophrenia patient cohort

预测动物模型中的抗精神病反应,研究神经免疫-多巴胺相互作用及其在精神分裂症患者队列中的转化

基本信息

项目摘要

The success of translation from molecular discoveries in animal models of schizophrenia to schizophrenia patients has so far been modest and this has raised questions on the value of translational research in psychiatry in general. Treatment resistance is a serious problem in schizophrenia where many patients do not respond to first line antipsychotics. This project shows a way out of the difficulties of translational psychiatry towards deepening insight into neuroimmune-dopamine interactions, identifying a specific immune biotype for a schizophrenia subset, and a blood test able to predict treatment response to antipsychotics in schizophrenia patients.We previously developed a transgenic rat model for sporadic schizophrenia with impaired signaling of the misassembled DISC1 protein featuring schizophrenia-relevant neuroanatomica, neurochemical and behavioral phenotypes related to aberrant dopamine homeostasis. We identified blood biomarkers in this animal model that were able to predict a subset of schizophrenia patients with high specificity. Both, overrepresentation of clozapine use in this subset, as well as decreased NudE-like 1 anzyme activity in this animal model, similar to treatment-resistant schizophrenia, support the hypothesis that animal model may be the first to model treatment-resistant schizophrenia, and that the associated, translatable immune biotype may indicate treatment response to antipsychotics.In this proposal, it will be tested 1. whether pharmacotherapy with amisulpride or clozapine differentially rescues key behavioral phenotypes of the animal model, whether a phenotype of treatment resistance in this animal model can be defined using behavioral, neuroanatomical and neuroinflammatory readouts, and whether the therapy response can be predicted by blood biomarkers. 2. The existing animal model will be modified to establish a two-hit model of a behavioral disorder where maternal immune activation is added to the already impaired signaling pathways. RNAseq-generated immune signatures from peripheral blood of experiments 1 and 2 will be translated into schizophrenia patients of the available COMBINE cohort from which blood prior to controled antipsychotics therapy is available. The COMBINE cohort is an existing independent and completed BMBF project aiming to prospectively test the clinical therapy response a amisulpride / olanzapine combination therapy over monotherapy of each antipsychotic.At the end of this project, fundamental insights into the interaction network of DISC1 protein-mediated signaling relevant for dopamine homeostasis, behavior, immune biotypes and response to antipsychotic treatment will be been gained. In addition, an immune biotype apparent in peripheral blood will have been identified that is potentially highly relevant for predicting clinical response for antipsychotic treatment.
迄今为止,从精神分裂症动物模型中的分子发现到精神分裂症患者的转化的成功是有限的,这就提出了关于转化研究在精神病学中的价值的问题。治疗抵抗是精神分裂症的一个严重问题,许多患者对一线抗精神病药物没有反应。该项目显示了一种摆脱转化精神病学困难的方法,以加深对神经免疫-多巴胺相互作用的了解,确定精神分裂症子集的特定免疫生物型,以及能够预测精神分裂症患者对抗精神病药物治疗反应的血液测试。我们以前开发了一种散发性精神分裂症的转基因大鼠模型,其错误组装的DISC 1蛋白的信号传导受损,具有精神分裂症相关的神经解剖学特征,与异常多巴胺稳态相关的神经化学和行为表型。我们在这种动物模型中鉴定了能够以高特异性预测精神分裂症患者子集的血液生物标志物。这两个,过度的氯氮平使用在这个子集中,以及减少NudE样1酶活性在这个动物模型中,类似于难治性精神分裂症,支持的假设,动物模型可能是第一个模型难治性精神分裂症,以及相关的,可翻译的免疫生物型可能表明抗精神病药物的治疗反应。氨磺必利或氯氮平的药物治疗是否不同地挽救动物模型的关键行为表型,是否可以使用行为、神经解剖学和神经炎症读数来定义该动物模型中的治疗抗性表型,以及是否可以通过血液生物标志物来预测治疗反应。2.将修改现有的动物模型,以建立行为障碍的两次打击模型,其中将母体免疫激活添加到已经受损的信号传导通路中。来自实验1和2的外周血的RNAseq生成的免疫特征将被翻译到可用的联合收割机群组的精神分裂症患者中,其中在受控抗精神病药物治疗之前的血液是可用的。联合收割机队列是一个现有的独立且已完成的BMBF项目,旨在前瞻性测试氨磺必利/奥氮平联合治疗相对于每种抗精神病药物单药治疗的临床治疗反应。在该项目结束时,将获得与多巴胺稳态、行为、免疫生物型和抗精神病药物治疗反应相关的DISC 1蛋白介导信号相互作用网络的基本见解。此外,还将鉴定出外周血中明显的免疫生物型,其与预测抗精神病药物治疗的临床应答可能高度相关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professor Dr. Carsten Korth其他文献

Professor Dr. Carsten Korth的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Professor Dr. Carsten Korth', 18)}}的其他基金

Identification and validation of key host cellular factors directing SARS-CoV-2 assembly and consequences for neuronal proteostasis
指导 SARS-CoV-2 组装的关键宿主细胞因子的鉴定和验证以及对神经元蛋白质稳态的影响
  • 批准号:
    458698796
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Abeta prion spreading: correlation with behavior, prion protein cofactor and effect of somatic mutations in novel animal models
Abeta朊病毒传播:与新型动物模型中行为、朊病毒蛋白辅因子和体细胞突变影响的相关性
  • 批准号:
    346939215
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Biochemical, cell biological and proteomical characterization of dysfunctional and posttranslationally modified DISC1 protein
功能失调和翻译后修饰的 DISC1 蛋白的生化、细胞生物学和蛋白质组学表征
  • 批准号:
    153683525
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Generation and biochemical characterization of a transgenic rat model for sporadic mental disease by overexpressing full length DISC1
通过过表达全长 DISC1 来构建散发性精神疾病转基因大鼠模型并进行生化表征
  • 批准号:
    153683831
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
    Research Grants

相似国自然基金

基于多模态磁共振探索迟发性运动障碍神经环路结构和功能异常
  • 批准号:
    81100999
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
NRG1-ErbB信号系统在谷氨酸功能低下大鼠模型和抗精神病药物药理机制中的作用
  • 批准号:
    30770775
  • 批准年份:
    2007
  • 资助金额:
    29.0 万元
  • 项目类别:
    面上项目

相似海外基金

Safety of Second Generation Antipsychotics for Adult Depression
第二代抗精神病药治疗成人抑郁症的安全性
  • 批准号:
    8875778
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Influences on Psychiatrist Prescribing of Antipsychotics
对精神科医生开抗精神病药处方的影响
  • 批准号:
    8233719
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Influences on Psychiatrist Prescribing of Antipsychotics
对精神科医生开抗精神病药处方的影响
  • 批准号:
    8451415
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Influences on Psychiatrist Prescribing of Antipsychotics
对精神科医生开抗精神病药处方的影响
  • 批准号:
    8605927
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Project 3: Elucidation of Biochemical and Behavioral Efficacies of Antipsychotics
项目 3:阐明抗精神病药的生化和行为功效
  • 批准号:
    8079093
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
METABOLIC EFFECTS OF ATYPICAL ANTIPSYCHOTICS
非典型抗精神病药的代谢作用
  • 批准号:
    8001278
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human
非典型抗精神病药:对人体肝葡萄糖和脂质代谢的影响
  • 批准号:
    7714499
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Schizophrenia Pharmacogenetics: cognition and symptom response to antipsychotics
精神分裂症药物遗传学:对抗精神病药物的认知和症状反应
  • 批准号:
    7660633
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human
非典型抗精神病药:对人体肝葡萄糖和脂质代谢的影响
  • 批准号:
    8101027
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human
非典型抗精神病药:对人体肝葡萄糖和脂质代谢的影响
  • 批准号:
    7924528
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了